PBAC's latest decision on Ixekizumab: Recommended with restriction (2023). Considered for Treatment of patients with non-radiographic ankylosing spondyloarthritis (nr-AxSpA) with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence, who have responded inadequately to, or are intolerant to, nonsteroidal anti-inflammatory drugs.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
5
first 2016
Submissions
5
2016 → 2023
Eligible population
Adult patients with active non-radiographic ankylosing spondyloarthritis with objective signs of inflammation (elevated CRP and/or MRI evidence) who have responded inadequately to or are intolerant to NSAIDs.
Therapy area
Rheumatology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
secukinumab, golimumab, certolizumab pegol
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Economic analysis was not independently evaluated as this was a Category 4 submission.
Risk sharing
Risk-sharing arrangement in place — IXE was recommended to be included within the current risk sharing arrangements (RSA) for GLM, CZP and SEC with no increase to the expenditure cap levels.
Submission history
Jul 2016: Not recommended · Authority Required
Jul 2018: Recommended with restriction · Authority Required
Jul 2020: Recommended with restriction · Authority Required
Nov 2021: Recommended with restriction · Authority Required
Jul 2023: Recommended with restriction · Authority Required